Mogrify signs collaborative research agreement with Astellas.

M2 EQUITYBITES-July 6, 2022-Mogrify signs collaborative research agreement with Astellas

(C)2022 M2 COMMUNICATIONS http://www.m2.com

Mogrify Limited, a UK-based biopharmaceutical company, announced on Tuesday that it has signed a collaborative research agreement with Japan-based Astellas for in vivo regenerative medicine approaches to address sensorineural hearing loss.

The collaboration aims to identify novel combinations of transcription factors involved in cell differentiation to generate new cochlear hair cells. Under the partnership, Astellas Gene Therapies is covering the research cost of the work and contributing its expertise in adeno-associated virus (AAV) based genetic medicine and translational capabilities to complete experiments in pre-clinical models. Mogrify is to exploit its bioinformatic platform, screening...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT